NMIBC

Oncology·MeSH: Non-Muscle Invasive Bladder Neoplasms

18 drugs in development·5 companies·8 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
nadofaragene firadenovec	CG Oncology, Inc. (CGON)
valrubicin	CG Oncology, Inc. (CGON)

Phase 3(2)

Drug	Company
bcg plus anktiva	ImmunityBio, Inc. (IBRX)
rMBCG	ImmunityBio, Inc. (IBRX)

Phase 2(10)

Phase 1(1)

Drug	Company
TYRA-300	Tyra Biosciences, Inc. (TYRA)

N/A(1)

Drug	Company
UGN-102	CG Oncology, Inc. (CGON)

Phase 1/Phase 2(2)

Drug	Company
BCG	ImmunityBio, Inc. (IBRX)
intravesical recombinant mycobacterium	ImmunityBio, Inc. (IBRX)

BioSniper tracks 18 drugs in development for NMIBC across 5 companies.

There are 8 clinical trials targeting NMIBC tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.